Target intelligence / Profile preview

Killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 5A (KIR2DL5A)

Target
KIR2DL5A
Molecular classification
Receptor, Immune receptor, Transmembrane glycoprotein, Immunoglobulin superfamily
01

Overview

Killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 5A (KIR2DL5A) is a protein expressed on the surface of natural killer (NK) cells and some T cells[1][3]. It is part of the KIR gene family, which encodes a family of broadly polymorphic receptors that regulate NK cell activity through their interaction with major histocompatibility complex (MHC) class I molecules, specifically subsets of human leukocyte antigen (HLA) class I[1][3]. KIR2DL5A belongs to the group of KIR proteins characterized by two extracellular immunoglobulin domains and a long cytoplasmic tail, which includes immune tyrosine-based inhibitory motifs (ITIMs) responsible for transmitting inhibitory signals and suppressing NK cell-mediated cytotoxicity[1][3]. The gene is located in the leukocyte receptor complex on chromosome 19q13.4 and displays significant polymorphism[1][2][3]. Variations in KIR gene content and alleles have been associated with immune-related diseases such as cancer, infectious diseases, autoimmune disorders, graft-versus-host disease, and other immune phenotypes[1][3]. Ligands for KIR2DL5A are still being clarified and not as well characterized as for other KIRs[3]. No directly approved drugs target KIR2DL5A, though modulation of KIR activity is an area of research for immunotherapy and transplant medicine.

Other names
KI2LAKiller cell immunoglobulin like receptor two Ig domains and long cytoplasmic tail 5AKIR2DL5NKAT11
02

Mechanism of action

Inhibits NK cell cytotoxicity via immune tyrosine-based inhibitory motifs (ITIMs) upon ligand engagement

03

Biological functions

Immune responseRegulation of natural killer (NK) cell activitySignal transduction (inhibitory signaling)
04

Disease associations

CancerInfectionAutoimmunityGraft-versus-host diseaseNeurofibroma
05

Safety considerations

High polymorphism and allelic diversity may complicate therapeutic targeting and predictabilityPotential for off-target modulation of immune response, especially in transplantation or autoimmunity context
06

Biomarkers

KIR gene cluster variation may serve as biomarker for immune response or allogeneic transplantation risk

Beyond the preview

Go deeper on Killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 5A (KIR2DL5A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 5A (KIR2DL5A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call